Privacy Policy
more

Giant Healthy Innovators – S2 Ep11

Giant Healthy Innovators – S2 Ep11

BARRY SHRIER [00:00:29] Hello and welcome to this week’s episode of Giants Healthy Innovators Live TV. My name is Barry Shrier and I’m your host. To begin with I’d like to say thank you very much to the tens of thousands of viewers that we have every week watching these episodes. We’re grateful for your patronage and we hope you find these episodes interesting and educational and entertaining. So thank you very much. I would also like to thank our sponsors. So thanks very much to Tech Data. Tech data is Europe’s largest distributor of I.T. technology and they’re building a very important European community of healthcare innovators. So if you’d like to learn more about that, please visit the Tech Data Web site. I’d also like to thank our sponsor, Grovelands, a European management consultancy. And I’d also like to thank our final sponsor, the Giant Health Event. So Giant, which is an acronym, Global Innovation and new technology giant, runs Europe’s largest and most valuable annual event, bringing together all of the stakeholders in healthcare, technology, innovation. And if you’d like to learn more about that, the website is www.giant.health. So thanks very much to Giant for your sponsorship. We appreciate that. Once again, my name is Barry Shrier and as you know, our format every week as we bring together a group of incredibly talented and capable and intelligent and motivated people who are doing great things in healthcare, technology and innovation. So what we’re gonna do is we’re going to ask everybody to introduce yourselves and then we’re gonna have a little conversation about some of the big issues in healthcare. Some of the challenges in society that health care is addressing and how with technology innovation, we might be able to improve health outcomes and deploy new technologies to gain better healthcare outcomes and to make a difference in the world of health care overall. So, again, thank you very much to our audience. Looking forward to having you with us today. So hello, everyone. Nice to see you guys. Thanks again for joining us. You as well. And really glad that you could join us. We really, really appreciate your time. So thank you very much. So, Phil, how are you?

 

PHILLIP P WEBB [00:02:28] I’m good, thanks. Very thank you very much for inviting me to do this.

 

BARRY SHRIER [00:02:31] It’s a pleasure. So if you don’t mind, if you can just introduce yourself, please, briefly and let us know what you’re up to in health care.

 

PHILLIP P WEBB [00:02:36] My names Dr. Phil Webb, I am director of innovation at Velindre University NHS Trust. Interestingly, when I met my chief executive yesterday, he had a new title for me. So his new title for me is Master of Spells and Potions.

 

BARRY SHRIER [00:02:49] Oh, Excellent. And what are you working on in particular? Any particular focus in within health care?

 

PHILLIP P WEBB [00:02:58] So we’re really looking to see how we can use artificial intelligence in a variety of different methods to see how it would improve both our systems and the interaction that patients have with our systems. So we’re exploring developing virtual assistants, training them to have conversations with patients about understanding the nature of the disease, the types of disease. And issues that they have about managing their conditions and as well as using more come formal applications of IoT to develop image classifiers in dermatology, ophthalmology, managing pixels and vox related images and understanding the technical side of those things.

 

BARRY SHRIER [00:03:36] Fascinating. Looking forward to hearing more about that. Yeah. Thank you for sharing. And hello, Liberty. nice to see you. Thanks for coming along. So please, if you can just introduce yourself and let us know what you’re up to these days.

 

LIBERTY FOREMAN [00:03:46] I’m Dr. Liberty Foreman and I’m a CEO, co-founder of DynamX Medical. And we try to integrate biochemistry and machine learning and infrared spectroscopy, clinical data and provide a point of care. Cancer diagnostic tool. So in the short term, we just try our samples. So every sample that comes to you for a cancer test, usually a biopsy. We scan it and we say within 15 seconds whether it’s healthy or not. And the idea is to reduce the bulk of samples, the great pathology by a half. And then in the long term, we’re looking to work with hisopathology to try to replace human.

 

BARRY SHRIER [00:04:25] Yeah. Fabulous. I’m sorry I didn’t hear, what’s the name of the business?

 

LIBERTY FOREMAN [00:04:31] DynamX Medical.

 

BARRY SHRIER [00:04:31] And is there a website?

 

LIBERTY FOREMAN [00:04:34] DynamXmedical.com.

 

BARRY SHRIER [00:04:43] So I love what you guys are doing. And I’m really pleased to hear more about it during the episode. And, um, hello, Sal. So you win the award for having travelled the farthest just to come and participate in this TV show. Thank you very much.

 

SAL DE MASI [00:04:55] You’re welcome, I appreciate it.

 

BARRY SHRIER [00:04:56] Where are you based?

 

SAL DE MASI [00:04:57] Toronto, Canada. Head office.

 

BARRY SHRIER [00:04:59] OK. Good stuff. So if you don’t mind, just introduce yourself briefly and let us know what you’re doing mainly.

 

SAL DE MASI [00:05:04] Sure. My name’s Sal Di Masi. I’m global director for Data Protection Solutions for Teknicor Corporation. I’m very passionate about the security and sustainability of customers data. And amongst many specialties that we carry in the organisation, which we heavily specialise in data protection solutions derived only from Delium Technologies.

 

BARRY SHRIER [00:05:29] Would I be right in assuming that there are data protection challenges?

 

SAL DE MASI [00:05:34] Very much so.

 

BARRY SHRIER [00:05:34] And Does the patient care about data protection?

 

SAL DE MASI [00:05:40] Yes, they do. Heavily any exposure of clients personal information is very important to, to them. It does matter.

 

BARRY SHRIER [00:05:49] Yes. So maybe what people will reveal all on social media, but they don’t want to reveal all if it’s medical data.

 

SAL DE MASI [00:05:57] Right. Because there may be conditions that, you know, they don’t want to disclose to the public.  you know, that’s very important to the hospital to make sure that their information is secure.

 

BARRY SHRIER [00:06:09] Absolutely. Yeah. Well done. Important stuff. thank you. And Charlotte. How are you?

 

CHARLOTTE CASEBOURNE [00:06:14] I’m good. Thank you for having me.

 

BARRY SHRIER [00:06:16] No, it’s a pleasure. Thank you. So, again, if you don’t mind, if you can introduce yourself and tell us what you’re doing these days.

 

CHARLOTTE CASEBOURNE [00:06:21] Absolutely. I’m sure case for my CEO and co-founder of a company called Theolytics. I also sit on the board of the UK by industry association. We feel it’s what we’re aiming to do is develop potentially curative therapies for cancer patients in the form of viruses that have the ability to selectively infect and kill cancer cells.

 

BARRY SHRIER [00:06:48] Wow. Have you got any of those with you tonight?

 

CHARLOTTE CASEBOURNE [00:06:50] I mean, they’re around us, these viruses are all over us all the time.

 

BARRY SHRIER [00:06:55] So is it reprogramming viruses? Or is it finding viruses which do the job and then deploying them?

 

CHARLOTTE CASEBOURNE [00:07:01] It’s a really interesting question. I mean, so the approach of using viruses as a way to kill cancer cells has been around for a while. We actually have a drug of this type approved already. And however, the field to date has focussed on reprogramming the cells and so adding genes in and taking genes out to try enhance them. So using technologies like crispr and to try and enhance either their selectivity of the infection or the potency. So their ability to kill the cells. We’re doing something slightly different. So we actually asked nature what the right answer is. So we developed these big libraries of viruses and then we use Darwinian selection to find the fittest virus variant for particular cancer indication.

 

BARRY SHRIER [00:07:46] Magnificent. No, absolutely stunning. Congratulations. I just love things like that. So thank you. And we are glad to have you on board. So we’ve been talking about a couple big issues in health care a little chat, before we started the episode tonight. One of them is data. And we were also talking about how you have this new thing, AI artificial intelligence, machine learning, spreadsheets, whatever it really is, which have an impact on this, don’t they? Do you guys feel like A.I. is a big topic? Is that a big thing? Is that going to be as impactful as other big developments like the stethoscope and things like that? Where are we in terms of AI? Phil, what’s your view?

 

PHILLIP P WEBB [00:08:29] So I would say that the rest of society has already embraced AI because mostly everything that you’re now doing is AI enable in some way. So your TV or your phone applications are all A.I. driven? Yes. Fridges are going to be AI driven. Your cars will be AI driven. The issue is how does public sector take advantage of the fact that there’s an acceptance socially that these things are happening? and then introduce them in a way that actually changes what we do in healthcare. That’s a big social issue. But it’s also a big tech issue because the technology has really taken over. The technology is there. Yeah. But it’s not necessarily socially. It’s not socially welcome. It’s not been dispersed in the way that we’re looking at applications for using. So guys like this who start developing how we would use it in specific environments to be critical to how we move this forward in the public sector.

 

BARRY SHRIER [00:09:16] Oh, interesting. Liberty.

 

LIBERTY FOREMAN [00:09:18] Will we have a device that’s OK. So we’re not selling it, but we’re trialling a device in hospitals that is based on AI and Machine learning and we don’t have an issue. Nurses use it. They like using it. It’s easy to use. We we do spend a lot of time making sure that whatever system we create is user friendly. Sure. But I think the answer is gradually, it’s like we’re not going to introduce something that’s unfortunately. So we’re not going introduce Rita tomorrow.

 

BARRY SHRIER [00:09:48] That’s next week.

 

LIBERTY FOREMAN [00:09:49] Next week? So we’re not going to introduce some sort of a hologram that’s completely artificially intelligent. Right. Tomorrow are we, but we might do it in 10 years if we gradually step it up. And I think that you can introduce AI into hospitals without people knowing it. And it be safe and safe.

 

BARRY SHRIER [00:10:10] Yes, does that link with data issues? Does AI bring larger data protection issues?

 

SAL DE MASI [00:10:15] Massive amounts of data exposure issues and also sustainability issues.

 

BARRY SHRIER [00:10:21] What does that mean? I haven’t heard that phrase about data.

 

SAL DE MASI [00:10:24] There’s so many moving parts in an in an AI in an AI’s capability. That, as she alluded to, you want to make sure it’s introduced in incremental steps. So finding a sustainable use case for it. That, you know, doesn’t cause too much destruction. And then build your foundation from the lower hanging fruit so that you don’t run into too many challenges when you move it forward.

 

BARRY SHRIER [00:10:49] Yes. Yeah. All right. Now, that’s extremely interesting. Does that overlap with your world? The whole AI and data sustainability and protection issue.

 

CHARLOTTE CASEBOURNE [00:10:59] Gosh, I suppose in our instance, we’re not yet we haven’t yet started clinical trials. And third, the kind of data that we’re working with, we do work with patient samples. And so in terms of our ability to make sure information is anonymised around each of them. Yes. And we’re being really careful in terms of consent and tracking all of that. That’s really important for us. And the place that we really leverage AI is empowering our platform. OK. And so I suppose it’s kind of slightly detached from the be patient setting. But we generate huge amounts of viral sequencing data and we’re applying lots of different methods to try and increase the diversity of the virus libraries that we’re working with. And so we essentially in the wet lab. And so in a scientific context, we apply a particular method. And then the readout we get tells us how to enhance, how to how to optimise or improve our protocol to get better and better doing what we’re doing. So I think I definitely see how it’s powering scientific discovery and more on the R&D side of things.

 

BARRY SHRIER [00:12:11]  Fascinating. Good stuff. Thank you for sharing that. I wonder if AI could help me to figure out how to print at home with my laptop. I’m not sure how far we are moving forward in technology, but that’s another issue.

 

PHILLIP P WEBB [00:12:30] Make yourself whatever stuff you want. There is a big issue about sustainability, though, right? We’ve got fantastic ability to do things that we never imagined we could do using power. You know, viral sequencing, genomic sequencing, stuff around complex data integration to be able to get an inference out of it. Yeah. We also need to start talking about infrastructure. OK. So when we have these things? We want to scale them up. Okay. What is going to power them? Right. What compute power do we have? as a society, as a community in the UK, in Wales.

 

BARRY SHRIER [00:13:02] Is that clearer or not. I mean, how can one say, look, five years from now? This is what we think we’ll need and is a roadmap to try and accomplish that? Or is it do to complicate it?

 

PHILLIP P WEBB [00:13:13] I think we need to start thinking about it and get the guys who are building it to start thinking about, well, actually, if we’re going to scale this up on size. And if what if I want Rita to interact with 220000 people who’ve got cancer? if you want to run even more viral sequencing all your stuff, I’m going to go do genomics. If society is going to run driverless cars. Who’s got the compute power to run all these things at the same time?

 

SAL DE MASI [00:13:37] That’s when you call Technikor, to help you figure it out. That’s already happening now.

 

BARRY SHRIER [00:13:43] That’s perfect. What’s your website address?

 

SAL DE MASI [00:13:45] Technikor.com. So that to answer your question doctor. That’s already in progress study. Those infrastructures already exist. They may not. They’re going to change a lot over the next five to ten years, but they already exist. They’re already being put into production. There’s already a lot of genome sequencing applications that are writing to those kind infrastructures. They’re purposely built to scale out, scale up and provide you incremental horsepower per say to achieve the end result.

 

BARRY SHRIER [00:14:16] Excellent. Is there anything like are you familiar with SETI, SETI at home? So about 10, 15 years ago you guys were too young. There was a movement called SETI the Search for Extraterrestrial Intelligence. And they created a good, I’m not sure how it worked, but basically it was saying, can we use your desktop PC at home at night while you’re sleeping? Because that’s spare processing capability and everybody could subscribe to it. And all these research scientists were wanting to listen to all the radio waves of outer space would use your desktop PC as a helper. Is there anything like that in health care. Would that be possible? Are we lacking computer power and could we tap on everybody’s laptop, which overnight isn’t doing anything or.

 

PHILLIP P WEBB [00:15:06] I don’t think that is required now. So you said the key term 10 to 15 years ago So the advancements that have happened in the last decade and in micro computing has 1000 times been improved. So the need to to reach out to an end user community and ask them for their horsepower and their PC, it’s irrelevant now. There’s plenty of horsepower available and computing power available in modern day technology.

 

PHILLIP P WEBB [00:15:33] So long as we had the early discussions about what we need to size, that’s a key bit of it. So we’re in a space now. We’ve got fantastic young people doing fantastic things. Yes. It’s a good time to sit down and say if this is the future that we’re trying to design for our population to meet their needs, what kinds of basic requirements do we need.

 

BARRY SHRIER [00:15:54] Are there discussions like that happening? Is there a view that right now this is the power we have in the average hospital trust or whatever? And we need ten or eight thousand times that in five years time. Is that kind of clear?

 

SAL DE MASI [00:16:07] I think those conversations lie in the hand of the partnership that’s formed between consultants and customer. So. A customer’s job is to explain their need and their requirement, the consultants job is to understand that and then find the translation that matches their need and technology. So as long as you’re having those conversations early on and the requirement is defined early on, then the technology can be set forth to assimilate those recruiters in the future.

 

BARRY SHRIER [00:16:38] Does that relate to you guys? Does that kind of appear on your radar?

 

LIBERTY FOREMAN [00:16:42] I think well probably might disagree with me, but I think that the problem isn’t the infrastructure. I think that the technology is there, but no one really knows how to implement that in a clinical setting. And there’s no acceptance for it yet or definitely not in the environments that I’ve seen. And we work in

 

BARRY SHRIER [00:16:59] Yes. So is the onus on you to drive that?

 

LIBERTY FOREMAN [00:17:04] There is one big Internet issue at Hospital sites. I mean, we have to do a lot of the stuff and we connect it we’d have to use a toggle because you can’t. Yeah, we can’t. We can’t. There’s no Internet in hospitals.

 

BARRY SHRIER [00:17:19] What’s a toggle?

 

LIBERTY FOREMAN [00:17:20] A dongle for the Internet. There is no Internet in hospitals. That’s good enough. So unless you’re seeing someone, you go through HL7 and I don’t know the exact process because we haven’t done it yet. But in order to get on to the NHS’s hospital connectivity. It’s very complicated. And it’s really difficult to find the person who you need to speak to do it in a hospital because nobody knows they exist. And so what you end up having to rely on and this is why I think 5G came up earlier, is you have to rely on sort of 3G 4G. And in most hospitals, the way that that they’re built. You just don’t get that connectivity.

 

PHILLIP P WEBB [00:18:05] So that is a really good design principle. So we need to be building by design so we can build by haphazard mass anymore Right. If you look at the NHS as a collection of 70 years worth of quilt weaving We’ve now got an ability using technology to not weave the quilt in the way that we weaved it before, but we have to be cognitive by design. So you design features in the way that you build in the future have got to accept the fact that cloud systems are an issue. Compute power is an issue. The guys need platforms to run their stuff off. That’s going to be seamless in the way that you’re looking to design buildings, hospital buildings, mobility into your workforce. And it’s a good time to do it because these guys are coming up with the ideas.

 

CHARLOTTE CASEBOURNE [00:18:54] How do you do that?

 

PHILLIP P WEBB [00:18:55] This is the debate. So the architecture of what we imagine the future could be needs to be a collaborative approach between the expertise that, quite frankly, sits in industry. The people with the ideas about doing something very differently and the NHS is a structure to accept the fact that it must change in order to optimise what it can do now with technology.

 

BARRY SHRIER [00:19:16] That’s interesting. Are there trade bodies? industry bodies? Did you mentioned you’re on the board of a is it a trade body is an industry association,.

 

CHARLOTTE CASEBOURNE [00:19:25] The bio industry association.

 

BARRY SHRIER [00:19:26] And do they talk about what’s their goal?

 

CHARLOTTE CASEBOURNE [00:19:29] Interesting. So the Bio Industry Association is a trade body that represents the life science biotech industry in the UK. It’s interesting because I suppose a lot of the discussions are around how we can support the life science sector in the UK all of these really innovative and emerging companies which are based on what the UK is incredible at, which is which is this world leading research institute. And to develop and to develop new drugs to ensure that patients have access to those drugs that are already available on the market. But the discussion around kind of, you know, the how the system, how the health system operates and is more from the perspective of how do we as a trade body support our members, which represent those companies that are ultimately developing new therapies for patients to access those patients through the system that is there.

 

SAL DE MASI [00:20:30] See, that’s the key, the people that represent the technology. They need to be included in these boards and in the discussions with the doctors. And with the ground level people. Because like I said, it’s their job to find the translation of what’s required at your level, what’s required at your level? What’s required at the ground level. And then consult on the appropriate technologies to achieve that.

 

BARRY SHRIER [00:20:55] Exactly. That’s what I was curious. Are there what you call them, steering groups like you have in the Internet itself in terms of Internet protocols? Are there steering groups in healthcare?

 

PHILLIP P WEBB [00:21:07] We’ve only just started to recognise the issues that are associated with delivering high level, excellent quality technology. We’ve only just started to understand what this actually means. So you know, the last thing that I want for my son who 16 living in the future. So I want him to have a good life, right? so we don’t want the situation where his flying car has got to come down on Tuesday because Charlotte’s got genomic sequencing on her viral studies because we haven’t got enough compute power. So we’re just starting to pull these things together and explore what these might mean. Because the last thing that we want to do is create an environment whereby liberty can’t scale up and roll out stuff for the whole of the NHS because we never thought about this in advance, because I didn’t speak to Sal about this stuff that we could do.

 

BARRY SHRIER [00:21:55] And Tech Data, don’t forget to add Tech Data as someone who can also help with the delivery of the infrastructure. Well, that reminds me at the giant health event this year. We’ve got some very interesting whole day conferences, one about gene therapy. We’re also looking at other issues. And Matt Hancock, of course, government minister, sacred of state for health care. Simon Stevens, the chief executive of the NHS. Matthew Gold, the chief executive of NHS X will all be there.

 

PHILLIP P WEBB [00:22:26] Not that you’re name dropping Barry right?

 

BARRY SHRIER [00:22:27] Not in the slightest. No, I would never consider doing that. But they’re all going to be there. And we hope you guys can come and you can have direct conversations with them, because the vibe I’m getting is that if there isn’t already there’s a challenge of setting up this, whatever you want to call it, this steering committee. This what you want to call it, bringing all the people, the stakeholders from different elements of the entire ecosystem together to map out this technology plus service delivery.

 

PHILLIP P WEBB [00:22:56] Environment. The bit that we have is having a bunch of young guys like this and girls like this doing stuff is incredibly rare. Sorry, it’s really patronising. Yeah. Forgive me. I’m old.

 

BARRY SHRIER [00:23:08] I mean part of the I’m part of young group, by the way.

 

PHILLIP P WEBB [00:23:12] It’s this is Diamond that you’ve actually got people who’ve got the imagination and that passion to want to do something. And what we can do is older guys in this environment is forget that we have to make them fly. We have to make this as easy as possible for them to do their thing, because if they do the things, society as a whole will improve. The patient’s outcomes will improve. The way that they live their lives in the future will improve. So the responsibility is on us to make it easy for them to do this.

 

BARRY SHRIER [00:23:46] Well, that’s easy. Now, that would clarify that. Are there other commercial issues as technology innovators are you guys finding well, the biggest challenge isn’t I don’t know the the the mathematics or the chemistry or the microbiology. Are there other issues? Is it. Is it fundraising? Is that a challenge? are recruiting people here in the UK versus hiring people in Eastern Europe had a quarter of the salary? I don’t know. What kind of challenges?

 

SAL DE MASI [00:24:15]  Cyber threats are probably the largest, largest factor. What keeps, you know, executives, I.T. directors, doctors up at night.

 

BARRY SHRIER [00:24:28] And that’s a cost bubble isn’t it? My very limited understanding is what was the big thing that which kind of froze hospitals and attacked Russia.

 

PHILLIP P WEBB [00:24:35] Ransomware viruses.

 

BARRY SHRIER [00:24:37] About a year or two or three ago. Cry, WannaCry.And, of course, the tabloid newspapers were up in arms, but then the leaders of hospital groups said, well, I’ve got 8 thousand people in my entire organisation and I have a 20 thousand pound annual budget for technical security or whatever. As you know, we can’t go down the road too much in this conversation about health care systems and budget and allocation. But are there ways of reducing the costs of cyber? What’s the word for it? Cyber security? And that type of thing. So we’re not reliant on just throw more money at it.

 

SAL DE MASI [00:25:14] Right. And again, it comes back to the previous conversation. It’s about having the proper discussions early on, OK, so that the consultants can can can describe to you what threats are available to negatively affect you and then provide you with consultations on the architectures that are required so that you buy it once and it lives with you for the term of your investment.  Right. And then that sets you up to be successful.

 

LIBERTY FOREMAN [00:25:43] If we’re talking about problems for innovators. Cyber threats have not had one, but maybe that’s what we’ve innovated and we get going in hospitals. I definitely think that’s a threat for hospitals but I think it’s a problem for innovators is knowledge transfer. Actually, when your when you’ve got an idea and you’re very much alone because it’s a new idea and you need to. So in my case, we had to find out how to run a clinical trial. How do I how do I do that? Who do I talk to? If you try and Google it, there’s not really much information available. And there’s not really that many people around you that have done it before. OK. So there are they’re just not really vocal about it.  And then you try and find out, OK, why I need to run a clinical trial to go into this hospital. Or what’s the infrastructure of the NHS to allow me to do that or what’s all the acronyms, these new acronyms that I have now have to learn? okay. Now we’re talking about security. You’ve got to anonymise all the data who am I going to talk to you about that. And I just don’t think that for us innovators, there’s that much community or space for us to do that. Not one place where we can go and say who can I can connect to that can help me like we were talking about earlier when you haven’t done a clinical trial before. I have. So maybe we can do that.

 

BARRY SHRIER [00:27:04] What would that be? A LinkedIn group? Would that be a government health department-sponsored weekly meetup?

 

PHILLIP P WEBB [00:27:15] If we talk about design. Right. You need to relook at the framework around research and development. So the framework around research and development is predicated on decades of work in medicines like making medicines safe with the pharma industry supporting us. I see that the transformation in digital technology is a different dynamic. Right. So in order for you to get a drug licenced in the UK, you’ve got to go through almost a 10 to 15 year procedure to generate your own space.

 

CHARLOTTE CASEBOURNE [00:27:45] Would you do it in the UK? I think this is a really interesting question. So speaking to Liberty’s point, I mean, access to their expertise, you know, I feel like we’ve been so lucky as a company to have identified these people that can support us navigating through some of these things for the first time. But, you know, it’s really interesting if you think about the ecosystem that we have in the UK in terms of knowledge transfer and you compare that to someone like Boston. It’s very different. And so we’ve got to come up with ways to firstly develop the skills where we might not have. You know, we’re recruiting people from all over the world that have the expertise that we need because they’re not here yet. And so then it’s a question of how do we attract them. Sure. And I think especially it’s been really interesting, I guess, Growing a company in Oxford where there are lots of spin outs popping up at the moment, it’s like finding the conventional you know, you have a very experienced leadership team that had done it before and then you recycle and you do it again you see in Boston. That’s not an option in the UK at the moment. So what you have the people stepping up. Haven’t done things before. And that means that the skillset that you need, I think is slightly different. You have to lose some of the hubris around knowing everything. Instead, the skillset that you need is the ability to identify people, to reach out, to say, I haven’t done this before and I don’t know. Can you help me? And then the ability to learn fast and to build out.

 

LIBERTY FOREMAN [00:29:32] Almost talking about going against the British culture.

 

BARRY SHRIER [00:29:36] That’s a fabulous subject for us to discuss on the next episode. And on that note. Very interesting, by the way, and a very relevant and I think that actually is something that we can develop. We have run out of time. I’m sorry to say so. I’m extremely grateful that you guys have joined us today. Thank you for coming along. I love all of the innovation and the cool things that you’re doing. We admire your passion and that makes a big difference. So thank you very much. What we do is we have a few minutes left, so we just want to go around the table, if that’s OK. And just a little tiny summary. Do you have a vision of the future? What are you guys trying to accomplish? Do you hope that in X years time we’re going to be able to do this because of what you’re doing? Something like that. So if you don’t mind, Charlotte, what would you like to see happening over the next few years or do you have a vision you’d like to share with us, please?

 

CHARLOTTE CASEBOURNE [00:30:24] Yeah, I think for me, I’d like to work towards a future in which there is equitable access to effective therapies for patients.

 

BARRY SHRIER [00:30:30] .Excellent. Thank you very much. Yeah. How about you Sal

 

SAL DE MASI [00:30:35] I’d like to see a more collaborative approach to two organisations engaging in wanting to truly understand the new technologies and find the right fit for them.

 

BARRY SHRIER [00:30:46] Excellent. Good stuff. Thank you. And I think we can do that, right? Absolutely.

 

LIBERTY FOREMAN [00:30:50] I’d like to see an integrated approach to diagnostics with A.I. and clinicians and biochemistry.

 

BARRY SHRIER [00:30:56] Perfect. Good. We should do that here on the table, shouldn’t we? More often. Yeah. Phil?

 

PHILLIP P WEBB [00:31:00] And my Prof once said if you can gaze into a crystal ball you in the room business. I’ve made my money and I would’ve been isolated somewhere else but I think if we can get together and create an environment where people can thrive in innovation and using technology in a supportive way, yes, we will be in a much better place in the future.

 

BARRY SHRIER [00:31:18] Excellent. Thank you for sharing that. Good stuff. Well, I appreciate your time. I’m sorry we’ve run out of time, but hopefully, we can continue the conversation in the pub. And so good to see you guys. And really, honestly, really grateful for your contribution. Thank You. So so thank you once again to our audience. We appreciate you watching this episode. This has been the Giant Health Event sponsored episode of our weekly program. Healthy Innovators Live TV. We’d also like to thank our sponsors thanks to Tech Data. They are Europe’s leading distributor of technology and Tech Data alongside IBM Watson Healthcare. We’ll be demonstrating a lot of their technologies and innovations in the healthcare sector at the Tech Data Village at the Giant Health Event this year. So you can learn more information about that at the website www.Giant.health. We’d also like to thank our other sponsor which has Grovelands. They’re one of Europe’s leading management consultancies. Thank you Grovelands for your support. And we’d also like to thank the finest, most high quality, most talented television, studio and production team in the world. Thank you, Disruptive Live. My name’s Barry Shrier. I appreciate your time. I hope you find this interesting. Thank you very much.